The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging

Brain Research

Volumn 1590, Issue 1, 2014, Pages 85-96

  Choi, Ji Kyung ^a   Carreras, Isabel ^b,c   Aytan, Nur ^b,c   Jenkins Sahlin, Eric ^a   Dedeoglu, Alpaslan ^a,b,c   Jenkins, Bruce G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Animal model; Magnetic resonance imaging; Magnetic resonance spectroscopy; Triple transgene

Indexed keywords

AMYLOID BETA PROTEIN; IBUPROFEN; INOSITOL; N ACETYLASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGING; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SIZE; CONTROLLED STUDY; HIPPOCAMPUS; HOUSING; IMAGING; MOUSE; MOUSE MODEL; NEUROCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TRANSGENE; ANIMAL; ANIMAL HOUSING; BRAIN CHEMISTRY; C57BL MOUSE; DRUG EFFECTS; GENETICS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

AGING; ALZHEIMER DISEASE; AMYGDALA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN CHEMISTRY; HIPPOCAMPUS; HOUSING, ANIMAL; HUMANS; IBUPROFEN; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSGENES;

EID: 84922806638     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.09.067     Document Type: Article

References (50)

1. Aytan, N., et al, 2013. Combination therapy in a transgenic model of Alzheimer's disease. Exp. Neurol. 250C, 228-238.
2. Badea, A., Johnson, G.A., Jankowsky, J.L., 2010. Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer's disease. NeuroImage 50, 416-427.
3. Birken, D.L., Oldendorf, W.H., 1989. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev 13, 23-31.
4. Borg, J., Chereul, E., 2008. Differential MRI patterns of brain atrophy in double or single transgenic mice for APP and/or SOD. J. Neurosci. Res. 86, 3275-3284.
5. Capsoni, S., Carucci, N.M., Cattaneo, A., 2012. Pathogen free conditions slow the onset of neurodegeneration in a mouse model of nerve growth factor deprivation. J. Alzheimers Dis. 31, 1-6.
6. Carmichael, O., et al, 2012. Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol. Aging 33 (1124 e31-41).
7. Carreras, I., et al, 2010. Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res. 1313, 192-201.
8. Carreras, I., et al, 2013. R-flurbiprofen improves tau, but not Ass pathology in a triple transgenic model of Alzheimer's disease. Brain Res. 1541, 115-127.
9. Chen, Y.C., et al, 2005. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 180, 705-715.
10. Choi, J.K., Dedeoglu, A., Jenkins, B.G., 2007. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 20, 216-237.
11. Choi, J.K., et al, 2010a. Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models. Neuropharmacology 59, 353-357.
12. Choi, J.K., et al, 2010b. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. 223, 377-384.
13. Decanniere, C., et al, 1995. Correlation of rapid changes in the average water diffusion constant and the concentrations of lactate and ATP breakdown products during global ischemia in cat brain. Magn. Reson. Med. 34, 343-352.
14. Dedeoglu, A., et al, 2004. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012, 60-65.
15. Ferrante, R.J., et al, 2000. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397.
16. Hillmann, A., et al, 2012. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33 (833 e39-50).
17. in t' Veld, B.A., et al., 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521.
18. Jack Jr., C.R., 2012. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 263, 344-361.
19. Jack Jr., C.R., et al., 2012. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch. Neurol. 69, 856-867.
20. Jantzen, P.T., et al, 2002. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246-2254.
21. Jaturapatporn, D., et al, 2012. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev. 2.
22. Jenkins, B., et al, 1996. Non-Invasive neurochemical analysis of focal excitotoxic lesions iin models of neurodegenerative illness using spectroscopic imaging. J. Cereb. Blood Flow Metab. 16, 450-461.
23. Jenkins, B.G., et al, 2000. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 74, 2108-2119.
24. Jenkins, B.G., et al, 2005. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J. Neurochem. 95, 553-562.
25. Johnson, K.A., et al, 2012. Brain imaging in Alzheimer disease. Cold Spring Harbor Perspect. Med 2, a006213.
26. Kantarci, K., et al, 2000. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55, 210-217.
27. Lim, G.P., et al, 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
28. Lim, G.P., et al, 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging. 22, 983-991.
29. Marjanska, M., et al, 2005. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A 102, 11906-11910.
30. Mastrangelo, M.A., Bowers, W.J., 2008. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 9, 81.
31. McGeer, P.L., McGeer, E.G., 2007. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging. 28, 639-647.
32. McKee, A.C., et al, 2008. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 1207, 225-236.
33. Mlynarik, V., et al, 2012. Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J. Alzheimers Dis 31 (Suppl. 3), S87-S99.
34. Mullane, K., Williams, M., 2013. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?. Biochem. Pharmacol 85, 289-305.
35. Oakley, H., et al, 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140.
36. Oddo, S., et al, 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
37. Oddo, S., et al, 2006a. A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 168, 184-194.
38. Oddo, S., et al, 2006b. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281, 1599-1604.
39. Oddo, S., et al, 2006c. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem.
40. Pettegrew, J.W., et al, 1997. Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann. N.Y. Acad. Sci 826, 282-306.
41. Pozzilli, P., et al, 1993. NOD mouse colonies around the world-recent facts and figures. Immunol. Today 14, 193-196.
42. Redwine, J.M., et al, 2003. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. U.S.A 100, 1381-1386.
43. Sabuncu, M.R., et al, 2011. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch. Neurol. 68, 1040-1048.
44. Shonk, T.K., et al, 1995. Probable Alzheimer disease: diagnosis with proton MR spectroscopy [see comments]. Radiology 195, 65-72.
45. Stewart, W.F., et al, 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
46. von Kienlin, M., et al, 2005. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 18, 32-39.
47. Wen, L., et al, 2008. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109-1113.
48. Westman, E., et al, 2010. Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. J. Alzheimers Dis. 22, 171-181.
49. Woo, D.C., et al, 2010. Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS. Behav. Brain Res. 211, 125-131.
50. Yang, D., et al, 2011. Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). NeuroImage 54, 2652-2658.